Systemic Mastocytosis Pipeline Summary

DelveInsight’s, “Systemic Mastocytosis - Pipeline Insight, 2026” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Systemic Mastocytosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Systemic Mastocytosis: Understanding

Systemic Mastocytosis: Overview

Systemic mastocytosis (SM) is a rare disorder characterized by the abnormal accumulation of clonal mast cells in extracutaneous organs, most commonly the bone marrow, liver, spleen, lymph nodes, and gastrointestinal tract. The disease is usually driven by activating mutations in the KIT gene, particularly KIT D816V, which promote mast-cell proliferation and survival. Clinical manifestations result from both mast-cell mediator release and tissue infiltration and may include flushing, pruritus, abdominal symptoms, anaphylaxis, bone pain, and organ dysfunction. SM ranges from indolent disease, which may remain stable for years, to advanced systemic mastocytosis, which can involve organ damage and associated hematologic malignancies.

Mast cells are immune cells of myeloid origin that are predominantly found within connective tissues. They can be activated through both IgE-dependent and non-IgE-mediated pathways, functioning as key effector cells in allergic and hypersensitivity reactions. In the IgE-dependent pathway, allergens cross-link IgE bound to mast-cell receptors, triggering activation and degranulation. Non-IgE activation can occur in response to various stimuli, including physical or emotional triggers, foods, medications such as opioids and NSAIDs, alcohol, heat, exercise, cytokines, venoms, and hormones. Activated mast cells release a range of mediators, including histamine, proteases, cytokines, growth factors, tumor necrosis factors, and phospholipases. Tryptase and chymase are abundant components of mast-cell granules, with tryptase serving as an important diagnostic biomarker because it is consistently released by mast cells.

The pathogenesis of mastocytosis involves the abnormal accumulation of mast cells in one or more tissues along with chronic or episodic release of mast-cell mediators. These cells contain various vasoactive substances that normally contribute to inflammatory and protective responses, but their excessive or widespread activation can produce symptoms resembling allergic or anaphylactic reactions. Mast-cell development and function are primarily regulated by the KIT gene, which encodes the CD117 transmembrane tyrosine kinase involved in mast-cell growth, survival, and migration. Activating KIT mutations can promote stem cell factor (SCF)-independent signaling and mast-cell proliferation, with the KIT D816V mutation being the most common driver alteration in systemic mastocytosis. Most KIT mutations are somatic and therefore generally not inherited, while additional genetic alterations, including TET2, JAK2, RAS, and FIP1L1-PDGFRA in cases associated with eosinophilia, may also contribute to disease pathogenesis.

Evaluation of systemic mastocytosis begins with a detailed medical history and assessment of symptoms and potential triggers of mast-cell activation, including medications, physical stimuli, stress, vaccines, contrast agents, and insect bites, along with any history of anaphylaxis. Initial investigations typically include complete blood count, renal and hepatic function tests, serum tryptase, albumin, and calcium, supplemented by bone marrow aspiration and biopsy with immunophenotyping for CD25 and tryptase and assessment for KIT mutations. Bone densitometry is also recommended because of the increased risk of bone loss. Additional investigations, such as abdominal CT, gastrointestinal endoscopy with biopsy, or liver and lymph-node biopsy, are guided by clinical findings. Diagnosis is established using WHO criteria based on characteristic mast-cell accumulation in bone marrow or extracutaneous tissues together with supportive findings such as elevated serum tryptase, aberrant CD25 expression, KIT D816V mutation, or increased atypical mast cells. Disease severity and organ involvement are further assessed using B and C findings, which include extensive mast-cell burden, organ enlargement, cytopenias, bone lesions or fractures, and gastrointestinal malabsorption associated with mast-cell infiltration.

Management of systemic mastocytosis is tailored to the disease subtype and symptoms. Anti-mediator therapies, including H1/H2 antihistamines and antileukotriene agents, are commonly used to control flushing, itching, gastrointestinal symptoms, and other mast-cell–mediated manifestations. Patients with recurrent anaphylaxis should avoid triggers, carry epinephrine, and may receive omalizumab when symptoms remain uncontrolled. Gastrointestinal symptoms may also be treated with cromolyn sodium or proton pump inhibitors, while calcium and vitamin D support bone health. Refractory disease may require glucocorticoids or cytoreductive therapies such as interferon-alfa, cladribine, or tyrosine kinase inhibitors. Aggressive systemic mastocytosis may require targeted or cytoreductive treatment, with hematopoietic cell transplantation considered for eligible patients. Management of SM with an associated hematologic neoplasm focuses on the associated disorder, while mast cell leukemia has no standardized treatment and generally carries a poor prognosis.

"Systemic Mastocytosis- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Systemic Mastocytosis pipeline landscape is provided which includes the disease overview and Systemic Mastocytosis treatment guidelines. The assessment part of the report embraces, in depth Systemic Mastocytosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Systemic Mastocytosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Systemic Mastocytosis R&D. The therapies under development are focused on novel approaches to treat/improve Systemic Mastocytosis.

Systemic Mastocytosis Emerging Drugs Chapters

This segment of the Systemic Mastocytosis report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Systemic Mastocytosis Emerging Drugs

Masitinib: AB Science

Masitinib is an investigational oral tyrosine kinase inhibitor developed by AB Science for the treatment of severely symptomatic indolent systemic mastocytosis (ISM) and smouldering systemic mastocytosis (SSM). It targets key kinases involved in mast-cell proliferation and activation, including wild-type c-KIT, Lyn, and Fyn, thereby reducing mast-cell activity and mediator release. Its mechanism may provide therapeutic activity irrespective of KIT D816V mutation status. In a Phase III study, masitinib demonstrated greater improvements than placebo in severe systemic mastocytosis-related symptoms, including pruritus, flushing, depression, and fatigue, as well as reductions in serum tryptase levels and Darier’s sign. According to company’s pipeline the therapy is in phase III stage of its development for the treatment of indolent systemic mastocytosis.

Elenestinib: Sanofi

Elenestinib (BLU-263) is an investigational, orally administered, next-generation KIT D816V inhibitor being developed by Sanofi for the treatment of indolent systemic mastocytosis (ISM) and smoldering systemic mastocytosis (SSM). It is designed to selectively inhibit the KIT D816V mutation, a key driver of abnormal mast-cell proliferation and activation, while exhibiting limited central nervous system penetration. Elenestinib is being evaluated in the HARBOR Phase II/III study in patients with ISM and SSM, with the aim of reducing mast-cell burden and improving disease-related symptoms. According to company’s pipeline the drug is in Phase III stage of it’s development for the treatment of Systemic Mastocytosis.

Further product details are provided in the report……..

Systemic Mastocytosis: Therapeutic Assessment

This segment of the report provides insights about the different Systemic Mastocytosis drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Systemic Mastocytosis
• There are approx. 5+ key companies which are developing the therapies for Systemic Mastocytosis. The companies which have their Systemic Mastocytosis drug candidates in the most advanced stage, i.e. Phase III include, AB Science.

• Phases

DelveInsight’s report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Systemic Mastocytosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Systemic Mastocytosis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Systemic Mastocytosis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Systemic Mastocytosis drugs.

Systemic Mastocytosis Report Insights

• Systemic Mastocytosis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Systemic Mastocytosis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Systemic Mastocytosis drugs?
• How many Systemic Mastocytosis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Systemic Mastocytosis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Systemic Mastocytosis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Systemic Mastocytosis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• AB Science
• Sanofi
• Stelix Biosciences

Key Products

• Mastinib
• Elenestinib
• STLX-2012